ISOAID, L.L.C.

IsoAid is a premier medical device manufacturer specializing in brachytherapy products for localized cancer treatment. The company manufactures and markets Advantage I-125 and Advantage Pd-103 radioactive seeds for prostate brachytherapy, eye plaque brachytherapy, and radioactive seed localization (RSL) for breast cancer diagnostics. IsoAid also manufactures IsoSphere, an FDA-cleared intraoperative intracavity brachytherapy device made of bioabsorbable material containing therapeutic amounts of Iodine-125 or Palladium-103 for breast cancer treatment. The company provides comprehensive brachytherapy services including custom seed loading, sterilization, independent assay, and plaque inventory rental. IsoAid seeds (models IAI-125A and IAPd-103A) are compatible with all major treatment planning software and are registered in the AAPM/RPC Brachytherapy sources registry. The company holds ISO 13485 and MDSAP certifications, confirming quality management system compliance. IsoAid offers flexible seed activity levels, rapid turnaround (5 business days), and 100% ADCL independent assay on loaded products. Through partnership with Eye Physics and Dr. Melvin Astrahan, the company provides access to advanced collimated eye plaques and proprietary 3D planning software. Products are FDA-cleared for therapeutic and diagnostic use in the U.S. and internationally.